Table 2.
Diagnostic and staging information at the time of initial diagnosis and prior to first radiotherapy treatment and at the time of salvage high-dose-rate brachytherapy (sHDR-BT) for 17 patients treated with sHDR-BT
| Parameter | At initial diagnosis | Prior to sHDR-BT | |
|---|---|---|---|
| PSA (ng/ml) | 8.2 (6.1-12.1) | 4.8 (2.8-8.3) | |
| T stage, n (%) | |||
| T1 | 9 (53) | 2 (12) | |
| T2 | 4 (24) | 7 (41) | |
| T3 | 4 (24) | 6 (35) | |
| T4 | 0 (0) | 2 (12) | |
| Gleason grade group*, n (%) | |||
| GG1 | 3 (18) | 0 (0) | |
| GG2 | 8 (47) | 7 (41) | |
| GG3 | 4 (24) | 5 (29) | |
| GG4 | 1 (6) | 1 (6) | |
| GG5 | 1 (6) | 4 (24) | |
| Number of cores positive, median (IQR) | 3 (2-5) | 6 (3-10) | |
| Number of cores sampled, median (IQR) | 12 (10-12) | 16 (12-17) | |
| Percentage of pattern 4 disease (%), median (IQR) | 25 (8-69) | 60 (30-100) | |
| Percentage of tissue positive (%), median (IQR) | 11 (6-30) | 17 (6-31) | |
| Absolute percentage of pattern 4 disease (%), median (IQR) | 4 (0-11) | 14 (2-20) | |
| Ultrasound gland volume (cc), median (IQR) | 35 (32-45) | 23 (19-25) | |
*
Synoptic Gleason grade group incorporated tissue from targeted biopsy specimen results when applicable